Valuation: OLIPASS Corporation

Market Cap 2.65TCr 1.78Cr 1.56Cr 1.44Cr 1.33Cr 2.5Cr 171.82Cr 2.56Cr 17Cr 6.76Cr 84Cr 6.7Cr 6.55Cr 289.68Cr P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 2.03TCr 1.37Cr 1.2Cr 1.1Cr 1.02Cr 1.92Cr 131.7Cr 1.96Cr 13Cr 5.18Cr 65Cr 5.14Cr 5.02Cr 222.04Cr EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
1,58,000
10 years 1,568
Extreme 1568
2,40,666.67
Manager TitleAgeSince
Chief Executive Officer 54 22/05/2025
Corporate Officer/Principal 34 28/11/2024
Comptroller/Controller/Auditor 67 31/03/2025
Director TitleAgeSince
Director/Board Member 54 28/11/2024
Director/Board Member 34 28/11/2024
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-90.57% 90.56L
-7.17%-4.39%+45.51%+79.00% 5.21TCr
+0.24%-1.54%+53.22%+71.85% 5.38TCr
+0.80%-6.31%+3.98%+423.29% 2.35TCr
-0.09%-0.01%-17.62%-14.67% 2.31TCr
-5.95%-2.58%+30.67%-9.58% 1.94TCr
-1.14%+0.03%+31.57%-30.42% 1.76TCr
-5.16%-7.00%+168.44%+306.37% 1.52TCr
-6.91%-5.83%+26.53%+636.97% 1.48TCr
+0.43%-1.03%+24.63%+191.40% 1.41TCr
Average -3.89%-6.95%+36.69%+156.36% 2.34TCr
Weighted average by Cap. -2.80%-2.36%+40.12%+144.10%

Financials

2021 2022
Net sales 85Cr 6L 5L 5L 4L 8L 5.52Cr 8L 55.21L 21.72L 2.7Cr 21.51L 21.04L 9.3Cr 229.6Cr 15.44L 13.49L 12.45L 11.48L 21.63L 15Cr 22.11L 1.49Cr 58.54L 7.28Cr 57.99L 56.72L 25Cr
Net income -2.51TCr -1.69Cr -1.48Cr -1.36Cr -1.26Cr -2.37Cr -162.78Cr -2.42Cr -16Cr -6.41Cr -80Cr -6.35Cr -6.21Cr -274.44Cr -2.42TCr -1.63Cr -1.42Cr -1.31Cr -1.21Cr -2.28Cr -156.52Cr -2.33Cr -16Cr -6.16Cr -77Cr -6.1Cr -5.97Cr -263.88Cr
Net Debt -1.83TCr -1.23Cr -1.07Cr -99.19L -91.43L -1.72Cr -118.45Cr -1.76Cr -12Cr -4.66Cr -58Cr -4.62Cr -4.52Cr -199.71Cr -619.5Cr -41.66L -36.41L -33.6L -30.97L -58.37L -40Cr -59.66L -4.02Cr -1.58Cr -20Cr -1.56Cr -1.53Cr -68Cr
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
78
  1. Stock Market
  2. Stocks
  3. A244460 Stock